sfa 23:0

SFA 23:0, commonly termed tricosanoic acid or tricosylic acid, is a long‑chain saturated fatty acid composed of 23 carbon atoms in a straight chain lacking double bonds. It belongs to the broader class of saturated fatty acids (SFAs), which are characterized by carbon chains fully saturated with hydrogen atoms. Saturated fatty acids are predominant in many animal fats and certain plant fats and have been studied extensively in nutrition science for their roles in metabolism and disease risk. SFA 23:0, specifically, is less abundant than many other SFAs such as palmitic (16:0) or stearic (18:0) acids but is detected in trace amounts in dietary fats and endogenous metabolism. Its odd‑chain configuration distinguishes it from the more common even‑chain SFAs and means its metabolic pathways involve unique precursors like propionyl‑CoA, which can originate from dietary sources, gut microbiota, or amino acid catabolism. SFA 23:0 has been identified in small quantities in edible plant oils like sesame, sunflower, and hempseed oils, as well as in dairy fats and some fungi. In the human body, circulating levels of very long‑chain saturated fatty acids (including those with 20 or more carbons) are influenced by both dietary intake and endogenous synthesis and have increasingly been studied as biomarkers in observational research. Although its presence is measurable in blood lipid fractions, there are currently no established dietary reference intakes specifically for SFA 23:0, and its health effects are typically interpreted within the context of overall saturated fat intake and lipid profiles.

SFA 23:0 functions primarily as a component of the complex mixture of fatty acids in dietary fats and circulating lipids. Like other saturated fatty acids, tricosanoic acid can be incorporated into triglycerides and phospholipids, influencing membrane structure and fluidity. Its odd carbon chain also means it arises via unique metabolic pathways, with propionyl‑CoA playing a role in its elongation and synthesis. Emerging research has investigated circulating levels of very long‑chain saturated fatty acids (VLSFAs, C20:0 through C24:0) as biomarkers for aspects of health and aging. For example, studies suggest higher circulating concentrations of certain VLSFAs (e.g., behenic acid, lignoceric acid) are associated with lower risks of unhealthy aging and age‑related chronic disease outcomes in older adults, indicating potential protective or integrative roles in metabolic health. While specific analyses on SFA 23:0 itself are limited, related cohort studies have demonstrated that higher plasma levels of comparable VLSFAs correlate with lower risks of incident unhealthy aging events, including chronic diseases and functional decline, although causality is not established and mechanisms remain under investigation. Additionally, recent observational work has explored associations between serum tricosanoic acid levels and cognitive function in older populations, with higher levels correlated with better performance on cognitive tests in some analyses. These relationships are complex and may reflect broader dietary and metabolic patterns rather than direct causal effects of SFA 23:0 alone.

Unlike essential micronutrients such as vitamins and minerals, specific dietary requirements for individual fatty acids like SFA 23:0 have not been established. Instead, health organizations provide guidelines for total saturated fatty acid intake as part of dietary patterns. Global recommendations from health authorities such as the World Health Organization suggest limiting total saturated fat to less than 10% of total energy intake to reduce elevated LDL cholesterol and cardiovascular disease risk. Within those guidelines, individual saturated fatty acids, including C23:0, are not separately quantified with specific recommended daily intakes due to their trace concentrations and limited evidence on direct health impacts. Therefore, the intake of tricosanoic acid in the diet is considered within the broader context of overall fat consumption and balance with unsaturated fats. Factors affecting individual needs involve age, sex, metabolic health, cardiovascular risk status, and genetic predispositions. For individuals with dyslipidemia or high cardiovascular risk, clinicians may recommend a stronger reduction of saturated fats and greater emphasis on monounsaturated and polyunsaturated fatty acids to favor beneficial lipid profiles. In contrast, populations with unique nutritional contexts, such as certain indigenous diets, may have differing saturated fat patterns yet do not consistently show proportional disease risk, reflecting the complexity of dietary fats and food matrices.

Because SFA 23:0 is not considered an essential nutrient and is consumed in small amounts relative to total fat intake, a deficiency of tricosanoic acid per se is not recognized in clinical medicine. There are no established clinical symptoms attributed to low dietary intake of C23:0. Instead, inadequate intake of fatty acids more broadly, especially essential polyunsaturated fatty acids (omega‑3 and omega‑6), can lead to symptoms such as poor growth, skin abnormalities, impaired immune function, and neurological deficits. While odd‑chain fatty acids like tricosanoic acid can accumulate differently in the context of metabolic imbalances, their presence in blood is not used diagnostically to define deficiency states. Laboratory measures of odd‑chain fatty acids may reflect metabolic conditions such as vitamin B12 deficiency, where propionyl‑CoA metabolism is disrupted, leading to accumulation of odd‑chain fatty acids. However, this accumulation pertains to metabolic dysfunction rather than a deficiency of SFA 23:0 itself.

Tricosanoic acid (C23:0) is present in trace amounts in a variety of dietary fats. Although specific amounts for C23:0 are not comprehensively cataloged in standard food composition databases, foods containing very long‑chain saturated fatty acids tend to include specific plant oils and animal fats. Sesame oil, sunflower oil, and hempseed oil have been indicated as dietary sources where tricosanoic acid may be detected. Dairy products such as whole milk, cheese, and yogurt contain a range of saturated fatty acids, including trace amounts of odd‑chain and very long‑chain fatty acids. The proportions of these fatty acids vary depending on animal diet, processing, species, and production methods. Other potential sources include certain wild mushrooms and plant leaves, which have been found to contain tricosanoic acid in lipid extractions. Dietary patterns rich in nuts and seeds (e.g., peanuts, macadamia nuts) also provide various VLSFAs, albeit in small quantities. Because C23:0 comprises a small fraction of overall fats in foods, focusing on balanced dietary patterns that include a variety of healthy fats ensures a diversity of fatty acids without excessive saturated fat intake.

SFA 23:0, like other long‑chain fatty acids, is absorbed via the small intestine following digestion of dietary triglycerides by pancreatic lipases. Long‑chain saturated fatty acids require incorporation into micelles facilitated by bile acids to be absorbed efficiently. Once absorbed, they are re‑esterified into triglycerides and packaged into chylomicrons for transport via lymphatics into the circulation. Factors that enhance absorption include concurrent intake of bile acid‑stimulating foods and overall dietary fat content, as bile acids are critical for emulsifying long‑chain fats. Conversely, conditions that impair bile production or pancreatic function can reduce absorption of long‑chain saturated fats. Bioavailability of individual very long‑chain fatty acids is influenced by their proportion within mixed dietary fat, overall digestion efficiency, and interactions with other macronutrients.

Given that SFA 23:0 is not recognized as an essential nutrient and occurs in trace amounts in dietary fats, there are no established supplements designed specifically to increase intake of tricosanoic acid. Supplemental saturated fats are generally not recommended, as increasing saturated fat intake beyond recommended limits can adversely affect LDL cholesterol and cardiovascular risk profiles. Instead, focus is placed on achieving a balance of dietary fats, with emphasis on sources of monounsaturated and polyunsaturated fatty acids.

Because SFA 23:0 is consumed in small quantities as part of overall saturated fat intake, there is no specific tolerable upper intake level established for this fatty acid. The toxicity concern relates to excessive saturation fat consumption as a category, which is associated with elevated LDL cholesterol and increased cardiovascular disease risk when exceeding recommendations. Public health guidelines recommend limiting total saturated fat to less than 10% of total energy to reduce LDL cholesterol and overall cardiovascular risk. High intakes of saturated fats from processed foods are particularly linked to adverse metabolic outcomes compared to whole‑food sources where the food matrix may mitigate risk.

There are no documented direct drug interactions specific to SFA 23:0 because it is not used therapeutically. However, high saturated fat diets can affect drug metabolism indirectly by altering lipid profiles that influence pharmacokinetics of lipophilic medications. For example, medications such as statin drugs used to lower cholesterol may show differential efficacy depending on baseline dietary saturated fat intake.